Disease · MONDO_0005009

congestive heart failure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. congestive heart failure. Diseases, record MONDO_0005009. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005009

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: congestive heart failure; Open Targets
Open Targets ID: MONDO_0005009; Open Targets
Other names: CCF - Congestive cardiac failure, CHF, CHF - Congestive heart failure, CHF NOS, Cardiac Failure Congestive, Cardiac failure, Cardiac failures, Cardiac insufficiency, Chronic heart failure, Congestive cardiac failure, Congestive heart failure (disorder), Congestive heart failure, unspecified, Congetive cardiac failure, Decompensation, Heart, Heart Decompensation, Heart failure, Myocardial Failure, congestive heart disease, failure, congestive heart, heart failure, congestive; Open Targets
Disease Ontology: DOID:6000; Disease Ontology
NCI Thesaurus: C3080; NCI Thesaurus
Highest stage of its drugs: Approval, for 53 of its 146 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs146

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NESIRITIDE	CHEMBL1201668	Protein	Approval	TTD	15	14	13	Drugs and targets
FUROSEMIDE	CHEMBL35	Small molecule	Approval	DailyMed and TTD	60	7	7	Drugs and targets
VALSARTAN	CHEMBL1069	Small molecule	Approval	DailyMed	30	7	7	Drugs and targets
SACUBITRIL	CHEMBL3137301	Small molecule	Approval	DailyMed	8	7	7	Drugs and targets
CARVEDILOL	CHEMBL723	Small molecule	Approval	DailyMed and TTD	16	3	2	Drugs and targets
SPIRONOLACTONE	CHEMBL1393	Small molecule	Approval	DailyMed and TTD	10	3	3	Drugs and targets
TORSEMIDE	CHEMBL1148	Small molecule	Approval	DailyMed and TTD	29	2	2	Drugs and targets
HYDROCHLOROTHIAZIDE	CHEMBL435	Small molecule	Approval	DailyMed	107	1	1	Drugs and targets
METOLAZONE	CHEMBL878	Small molecule	Approval	DailyMed	15	1	1	Drugs and targets
EPLERENONE	CHEMBL1095097	Small molecule	Approval	DailyMed	10	1	1	Drugs and targets

1 to 10 of 146

See all 146 drugs

Targets137

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	12	Adrenergic receptor agonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	9	Adrenergic receptor agonist; Adrenergic receptor beta agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	7	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Approval	https://conductscience.org/library/genes/6559	Drugs and targets
ACE	Angiotensin-converting enzyme	6	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
ADRA1A	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	5	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	5	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	5	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2983	Drugs and targets

1 to 10 of 137

See all 137 targets

Trials125

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01035255	This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure	Phase 3	8,442	2015-09-07	Heart Failure With Reduced Ejection Fraction	SACUBITRIL, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00004562	Occluded Artery Trial (OAT)	Phase 3	2,201	2013-02-11	Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive, Heart Failure	ASPIRIN	Its record names the disease	ClinicalTrials.gov
NCT03342690	Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)		1,165	2021-06-28	Chronic Heart Failure	EPLERENONE	Its record names the disease	ClinicalTrials.gov
NCT00486759	A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma	Phase 3	787	2012-12-31	B-cell Lymphoma	BEVACIZUMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00078286	Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure	Phase 2/3	469	2013-02-27	Heart Failure, Congestive, Chronic Heart Failure, Depression	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT02468232	Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction	Phase 3	225	2023-12-08	Heart Failure With Reduced Ejection Fraction (HF-rEF)	SACUBITRIL, VALSARTAN	Its record names the disease	ClinicalTrials.gov
NCT00837902	Genetic Determinants of Response to Beta Blockade	Not applicable	154	2018-11-30	Healthy	ATENOLOL	Its record names the disease	ClinicalTrials.gov
NCT00462670	A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)	Phase 3	110	2014-02-04	Edema, Cardiac	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT01357850	A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure	Phase 2	82	2014-10-01	Heart Failure, Congestive	ALBIGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT00812253	Intensive Glycemic Control for Congestive Heart Failure Exacerbation	Phase 2	74	2014-08-07	Congestive Heart Failure, Diabetes Mellitus	INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 125

See all 125 trials

Comparisons in its trials17

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
LCZ696 vs Enalapril: serious adverse events	1,937 of 4,203	2,142 of 4,229	8,432	NCT01035255	Trial comparisons
LCZ696 vs Enalapril: Number of Patients With First Confirmed Renal Dysfunction	94 of 4,187	108 of 4,212	8,399	NCT01035255	Trial comparisons
LCZ696 vs Enalapril: Number of Patients - All-cause Mortality	711 of 4,187	835 of 4,212	8,399	NCT01035255	Trial comparisons
Percutaneous Coronary Intervention Group vs Medical Therapy Group: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)	230 of 1,101	219 of 1,100	2,201	NCT00004562	Trial comparisons
Percutaneous Coronary Intervention Group vs Medical Therapy Group: serious adverse events	226 of 1,101	227 of 1,100	2,201	NCT00004562	Trial comparisons
Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events	224 of 395	173 of 386	781	NCT00486759	Trial comparisons
Sertraline vs Placebo: serious adverse events	57 of 234	63 of 235	469	NCT00078286	Trial comparisons
White Participants--Atenolol vs Black Participants-Atenolol: deaths from any cause	0 of 85	0 of 69	154	NCT00837902	Trial comparisons
White Participants--Atenolol vs Black Participants-Atenolol: serious adverse events	0 of 85	0 of 69	154	NCT00837902	Trial comparisons
OPC-41061 15mg vs Placebo: serious adverse events	2 of 53	7 of 57	110	NCT00462670	Trial comparisons

1 to 10 of 17

See all 17 comparisons in its trials

Papers from its trials154

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36573717	RESULT	2	PubMed
34897419	RESULT	1	PubMed
30825073	RESULT	1	PubMed
27653447	RESULT	1	PubMed
27431783	RESULT	1	PubMed
26573925	RESULT	1	PubMed
26542491	RESULT	1	PubMed
23713082	RESULT	1	PubMed
22562554	RESULT	1	PubMed
22025606	RESULT	1	PubMed

1 to 10 of 154

See all 154 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005009

GET https://conductscience.org/api/diseases/v1/MONDO_0005009/drugs?page=2

API reference For AI assistants